FN1 and neoplasm: For instance, PYX-201, an ADC targeting the extradomain B (EDB) of fibronectin—an oncofetal antigen abundant in the tumor stroma—has recently received FDA Fast Track designation based on promising Phase 1 data, highlighting the potential of stroma-directed strategies to overcome the limitations of the gastric TME [54].